Global Renal Biomarker

Renal Biomarker Comprehensive Study by Type (Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, Pharmacodynamic Biomarkers), Application (Hospital, Diagnostic Laboratory, Other), Diagnostic Technique (Enzyme-linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS)) Players and Region - Global Market Outlook to 2026

Renal Biomarker Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
A biomarker is also known as a biologic marker is a measurable indicator of a specific biological state, particularly one relevant to the risk for, the presence of, or the stage of the disease. Though historically the term often mentioned to a physical trait or physiological metric, it now normally refers to products of genomic, metobolomic, and proteomic research. Biomarkers can be used clinically to screen for, diagnose, or monitor the movement of diseases and to guide molecularly targeted therapy or assess therapeutic response.This growth is primarily driven by Growing Prevalence of Various Kidney-Related Diseases and High Prevalence of Diabetes and High Blood Pressure, Leading Cause of Renal Diseases.

Globally, a noticeable market trend is evident Rapid Technological Advancements in the Field Of Genetics. Major Players, such as Beckman Coulter Inc. (United States), Thermo Fisher Scientific Inc. (United States), Abbott Molecular Inc. (United States), Bioporto AS (Denmark), Astute Medical Inc. (United States), Randox Laborotories Ltd (United Kingdom), Siemens Healthineers (Germany), Cobo Scientific Biomedical Research (Denmark), F. Hoffmann-La Roche Ag (Switzerland) and Biomerieux (France) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On March 19, 2019 - Baxter International Inc., a global leader in acute care, and bioMérieux, a world leader in the field of in-vitro diagnostics, announced an agreement to develop future biomarkers with the goal to rapidly identify and inform the treatment of acute kidney injury (AKI).

Market Drivers
  • Growing Prevalence of Various Kidney-Related Diseases
  • High Prevalence of Diabetes and High Blood Pressure, Leading Cause of Renal Diseases

Market Trend
  • Rapid Technological Advancements in the Field Of Genetics

Restraints
  • Issues Regarding Regulatory and Reimbursement Systems

Opportunities
Rising R&D Investments in the Field of Genetics
Challenges
Stringent Regulatory Framework

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Renal Biomarker Study Sheds Light on
— The Renal Biomarker Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Renal Biomarker industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Renal Biomarker industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Diagnostic Biomarkers
  • Prognostic Biomarkers
  • Predictive Biomarkers
  • Pharmacodynamic Biomarkers
By Application
  • Hospital
  • Diagnostic Laboratory
  • Other
By Diagnostic Technique
  • Enzyme-linked Immunosorbent Assay
  • Particle-Enhanced Turbidimetric Immunoassay (PETIA)
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay (CLIA)
  • Liquid Chromatography Mass Spectrometry (LS-MS)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Various Kidney-Related Diseases
      • 3.2.2. High Prevalence of Diabetes and High Blood Pressure, Leading Cause of Renal Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Framework
    • 3.4. Market Trends
      • 3.4.1. Rapid Technological Advancements in the Field Of Genetics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Renal Biomarker, by Type, Application, Diagnostic Technique and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Renal Biomarker (Value)
      • 5.2.1. Global Renal Biomarker by: Type (Value)
        • 5.2.1.1. Diagnostic Biomarkers
        • 5.2.1.2. Prognostic Biomarkers
        • 5.2.1.3. Predictive Biomarkers
        • 5.2.1.4. Pharmacodynamic Biomarkers
      • 5.2.2. Global Renal Biomarker by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Diagnostic Laboratory
        • 5.2.2.3. Other
      • 5.2.3. Global Renal Biomarker by: Diagnostic Technique (Value)
        • 5.2.3.1. Enzyme-linked Immunosorbent Assay
        • 5.2.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
        • 5.2.3.3. Colorimetric Assay
        • 5.2.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
        • 5.2.3.5. Liquid Chromatography Mass Spectrometry (LS-MS)
      • 5.2.4. Global Renal Biomarker Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Renal Biomarker (Price)
      • 5.3.1. Global Renal Biomarker by: Type (Price)
  • 6. Renal Biomarker: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Beckman Coulter Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Molecular Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bioporto AS (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astute Medical Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Randox Laborotories Ltd (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siemens Healthineers (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cobo Scientific Biomedical Research (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche Ag (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biomerieux (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Renal Biomarker Sale, by Type, Application, Diagnostic Technique and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Renal Biomarker (Value)
      • 7.2.1. Global Renal Biomarker by: Type (Value)
        • 7.2.1.1. Diagnostic Biomarkers
        • 7.2.1.2. Prognostic Biomarkers
        • 7.2.1.3. Predictive Biomarkers
        • 7.2.1.4. Pharmacodynamic Biomarkers
      • 7.2.2. Global Renal Biomarker by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Diagnostic Laboratory
        • 7.2.2.3. Other
      • 7.2.3. Global Renal Biomarker by: Diagnostic Technique (Value)
        • 7.2.3.1. Enzyme-linked Immunosorbent Assay
        • 7.2.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)
        • 7.2.3.3. Colorimetric Assay
        • 7.2.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)
        • 7.2.3.5. Liquid Chromatography Mass Spectrometry (LS-MS)
      • 7.2.4. Global Renal Biomarker Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Renal Biomarker (Price)
      • 7.3.1. Global Renal Biomarker by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Renal Biomarker: by Type(USD Million)
  • Table 2. Renal Biomarker Diagnostic Biomarkers , by Region USD Million (2015-2020)
  • Table 3. Renal Biomarker Prognostic Biomarkers , by Region USD Million (2015-2020)
  • Table 4. Renal Biomarker Predictive Biomarkers , by Region USD Million (2015-2020)
  • Table 5. Renal Biomarker Pharmacodynamic Biomarkers , by Region USD Million (2015-2020)
  • Table 6. Renal Biomarker: by Application(USD Million)
  • Table 7. Renal Biomarker Hospital , by Region USD Million (2015-2020)
  • Table 8. Renal Biomarker Diagnostic Laboratory , by Region USD Million (2015-2020)
  • Table 9. Renal Biomarker Other , by Region USD Million (2015-2020)
  • Table 10. Renal Biomarker: by Diagnostic Technique(USD Million)
  • Table 11. Renal Biomarker Enzyme-linked Immunosorbent Assay , by Region USD Million (2015-2020)
  • Table 12. Renal Biomarker Particle-Enhanced Turbidimetric Immunoassay (PETIA) , by Region USD Million (2015-2020)
  • Table 13. Renal Biomarker Colorimetric Assay , by Region USD Million (2015-2020)
  • Table 14. Renal Biomarker Chemiluminescent Enzyme Immunoassay (CLIA) , by Region USD Million (2015-2020)
  • Table 15. Renal Biomarker Liquid Chromatography Mass Spectrometry (LS-MS) , by Region USD Million (2015-2020)
  • Table 16. South America Renal Biomarker, by Country USD Million (2015-2020)
  • Table 17. South America Renal Biomarker, by Type USD Million (2015-2020)
  • Table 18. South America Renal Biomarker, by Application USD Million (2015-2020)
  • Table 19. South America Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 20. Brazil Renal Biomarker, by Type USD Million (2015-2020)
  • Table 21. Brazil Renal Biomarker, by Application USD Million (2015-2020)
  • Table 22. Brazil Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 23. Argentina Renal Biomarker, by Type USD Million (2015-2020)
  • Table 24. Argentina Renal Biomarker, by Application USD Million (2015-2020)
  • Table 25. Argentina Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 26. Rest of South America Renal Biomarker, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Renal Biomarker, by Application USD Million (2015-2020)
  • Table 28. Rest of South America Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 29. Asia Pacific Renal Biomarker, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Renal Biomarker, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Renal Biomarker, by Application USD Million (2015-2020)
  • Table 32. Asia Pacific Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 33. China Renal Biomarker, by Type USD Million (2015-2020)
  • Table 34. China Renal Biomarker, by Application USD Million (2015-2020)
  • Table 35. China Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 36. Japan Renal Biomarker, by Type USD Million (2015-2020)
  • Table 37. Japan Renal Biomarker, by Application USD Million (2015-2020)
  • Table 38. Japan Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 39. India Renal Biomarker, by Type USD Million (2015-2020)
  • Table 40. India Renal Biomarker, by Application USD Million (2015-2020)
  • Table 41. India Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 42. South Korea Renal Biomarker, by Type USD Million (2015-2020)
  • Table 43. South Korea Renal Biomarker, by Application USD Million (2015-2020)
  • Table 44. South Korea Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 45. Taiwan Renal Biomarker, by Type USD Million (2015-2020)
  • Table 46. Taiwan Renal Biomarker, by Application USD Million (2015-2020)
  • Table 47. Taiwan Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 48. Australia Renal Biomarker, by Type USD Million (2015-2020)
  • Table 49. Australia Renal Biomarker, by Application USD Million (2015-2020)
  • Table 50. Australia Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Renal Biomarker, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Renal Biomarker, by Application USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 54. Europe Renal Biomarker, by Country USD Million (2015-2020)
  • Table 55. Europe Renal Biomarker, by Type USD Million (2015-2020)
  • Table 56. Europe Renal Biomarker, by Application USD Million (2015-2020)
  • Table 57. Europe Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 58. Germany Renal Biomarker, by Type USD Million (2015-2020)
  • Table 59. Germany Renal Biomarker, by Application USD Million (2015-2020)
  • Table 60. Germany Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 61. France Renal Biomarker, by Type USD Million (2015-2020)
  • Table 62. France Renal Biomarker, by Application USD Million (2015-2020)
  • Table 63. France Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 64. Italy Renal Biomarker, by Type USD Million (2015-2020)
  • Table 65. Italy Renal Biomarker, by Application USD Million (2015-2020)
  • Table 66. Italy Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 67. United Kingdom Renal Biomarker, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Renal Biomarker, by Application USD Million (2015-2020)
  • Table 69. United Kingdom Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 70. Netherlands Renal Biomarker, by Type USD Million (2015-2020)
  • Table 71. Netherlands Renal Biomarker, by Application USD Million (2015-2020)
  • Table 72. Netherlands Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 73. Rest of Europe Renal Biomarker, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Renal Biomarker, by Application USD Million (2015-2020)
  • Table 75. Rest of Europe Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 76. MEA Renal Biomarker, by Country USD Million (2015-2020)
  • Table 77. MEA Renal Biomarker, by Type USD Million (2015-2020)
  • Table 78. MEA Renal Biomarker, by Application USD Million (2015-2020)
  • Table 79. MEA Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 80. Middle East Renal Biomarker, by Type USD Million (2015-2020)
  • Table 81. Middle East Renal Biomarker, by Application USD Million (2015-2020)
  • Table 82. Middle East Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 83. Africa Renal Biomarker, by Type USD Million (2015-2020)
  • Table 84. Africa Renal Biomarker, by Application USD Million (2015-2020)
  • Table 85. Africa Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 86. North America Renal Biomarker, by Country USD Million (2015-2020)
  • Table 87. North America Renal Biomarker, by Type USD Million (2015-2020)
  • Table 88. North America Renal Biomarker, by Application USD Million (2015-2020)
  • Table 89. North America Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 90. United States Renal Biomarker, by Type USD Million (2015-2020)
  • Table 91. United States Renal Biomarker, by Application USD Million (2015-2020)
  • Table 92. United States Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 93. Canada Renal Biomarker, by Type USD Million (2015-2020)
  • Table 94. Canada Renal Biomarker, by Application USD Million (2015-2020)
  • Table 95. Canada Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 96. Mexico Renal Biomarker, by Type USD Million (2015-2020)
  • Table 97. Mexico Renal Biomarker, by Application USD Million (2015-2020)
  • Table 98. Mexico Renal Biomarker, by Diagnostic Technique USD Million (2015-2020)
  • Table 99. Renal Biomarker: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Renal Biomarker: by Type(USD Million)
  • Table 111. Renal Biomarker Diagnostic Biomarkers , by Region USD Million (2021-2026)
  • Table 112. Renal Biomarker Prognostic Biomarkers , by Region USD Million (2021-2026)
  • Table 113. Renal Biomarker Predictive Biomarkers , by Region USD Million (2021-2026)
  • Table 114. Renal Biomarker Pharmacodynamic Biomarkers , by Region USD Million (2021-2026)
  • Table 115. Renal Biomarker: by Application(USD Million)
  • Table 116. Renal Biomarker Hospital , by Region USD Million (2021-2026)
  • Table 117. Renal Biomarker Diagnostic Laboratory , by Region USD Million (2021-2026)
  • Table 118. Renal Biomarker Other , by Region USD Million (2021-2026)
  • Table 119. Renal Biomarker: by Diagnostic Technique(USD Million)
  • Table 120. Renal Biomarker Enzyme-linked Immunosorbent Assay , by Region USD Million (2021-2026)
  • Table 121. Renal Biomarker Particle-Enhanced Turbidimetric Immunoassay (PETIA) , by Region USD Million (2021-2026)
  • Table 122. Renal Biomarker Colorimetric Assay , by Region USD Million (2021-2026)
  • Table 123. Renal Biomarker Chemiluminescent Enzyme Immunoassay (CLIA) , by Region USD Million (2021-2026)
  • Table 124. Renal Biomarker Liquid Chromatography Mass Spectrometry (LS-MS) , by Region USD Million (2021-2026)
  • Table 125. South America Renal Biomarker, by Country USD Million (2021-2026)
  • Table 126. South America Renal Biomarker, by Type USD Million (2021-2026)
  • Table 127. South America Renal Biomarker, by Application USD Million (2021-2026)
  • Table 128. South America Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 129. Brazil Renal Biomarker, by Type USD Million (2021-2026)
  • Table 130. Brazil Renal Biomarker, by Application USD Million (2021-2026)
  • Table 131. Brazil Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 132. Argentina Renal Biomarker, by Type USD Million (2021-2026)
  • Table 133. Argentina Renal Biomarker, by Application USD Million (2021-2026)
  • Table 134. Argentina Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 135. Rest of South America Renal Biomarker, by Type USD Million (2021-2026)
  • Table 136. Rest of South America Renal Biomarker, by Application USD Million (2021-2026)
  • Table 137. Rest of South America Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 138. Asia Pacific Renal Biomarker, by Country USD Million (2021-2026)
  • Table 139. Asia Pacific Renal Biomarker, by Type USD Million (2021-2026)
  • Table 140. Asia Pacific Renal Biomarker, by Application USD Million (2021-2026)
  • Table 141. Asia Pacific Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 142. China Renal Biomarker, by Type USD Million (2021-2026)
  • Table 143. China Renal Biomarker, by Application USD Million (2021-2026)
  • Table 144. China Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 145. Japan Renal Biomarker, by Type USD Million (2021-2026)
  • Table 146. Japan Renal Biomarker, by Application USD Million (2021-2026)
  • Table 147. Japan Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 148. India Renal Biomarker, by Type USD Million (2021-2026)
  • Table 149. India Renal Biomarker, by Application USD Million (2021-2026)
  • Table 150. India Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 151. South Korea Renal Biomarker, by Type USD Million (2021-2026)
  • Table 152. South Korea Renal Biomarker, by Application USD Million (2021-2026)
  • Table 153. South Korea Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 154. Taiwan Renal Biomarker, by Type USD Million (2021-2026)
  • Table 155. Taiwan Renal Biomarker, by Application USD Million (2021-2026)
  • Table 156. Taiwan Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 157. Australia Renal Biomarker, by Type USD Million (2021-2026)
  • Table 158. Australia Renal Biomarker, by Application USD Million (2021-2026)
  • Table 159. Australia Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Renal Biomarker, by Type USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Renal Biomarker, by Application USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 163. Europe Renal Biomarker, by Country USD Million (2021-2026)
  • Table 164. Europe Renal Biomarker, by Type USD Million (2021-2026)
  • Table 165. Europe Renal Biomarker, by Application USD Million (2021-2026)
  • Table 166. Europe Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 167. Germany Renal Biomarker, by Type USD Million (2021-2026)
  • Table 168. Germany Renal Biomarker, by Application USD Million (2021-2026)
  • Table 169. Germany Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 170. France Renal Biomarker, by Type USD Million (2021-2026)
  • Table 171. France Renal Biomarker, by Application USD Million (2021-2026)
  • Table 172. France Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 173. Italy Renal Biomarker, by Type USD Million (2021-2026)
  • Table 174. Italy Renal Biomarker, by Application USD Million (2021-2026)
  • Table 175. Italy Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 176. United Kingdom Renal Biomarker, by Type USD Million (2021-2026)
  • Table 177. United Kingdom Renal Biomarker, by Application USD Million (2021-2026)
  • Table 178. United Kingdom Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 179. Netherlands Renal Biomarker, by Type USD Million (2021-2026)
  • Table 180. Netherlands Renal Biomarker, by Application USD Million (2021-2026)
  • Table 181. Netherlands Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 182. Rest of Europe Renal Biomarker, by Type USD Million (2021-2026)
  • Table 183. Rest of Europe Renal Biomarker, by Application USD Million (2021-2026)
  • Table 184. Rest of Europe Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 185. MEA Renal Biomarker, by Country USD Million (2021-2026)
  • Table 186. MEA Renal Biomarker, by Type USD Million (2021-2026)
  • Table 187. MEA Renal Biomarker, by Application USD Million (2021-2026)
  • Table 188. MEA Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 189. Middle East Renal Biomarker, by Type USD Million (2021-2026)
  • Table 190. Middle East Renal Biomarker, by Application USD Million (2021-2026)
  • Table 191. Middle East Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 192. Africa Renal Biomarker, by Type USD Million (2021-2026)
  • Table 193. Africa Renal Biomarker, by Application USD Million (2021-2026)
  • Table 194. Africa Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 195. North America Renal Biomarker, by Country USD Million (2021-2026)
  • Table 196. North America Renal Biomarker, by Type USD Million (2021-2026)
  • Table 197. North America Renal Biomarker, by Application USD Million (2021-2026)
  • Table 198. North America Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 199. United States Renal Biomarker, by Type USD Million (2021-2026)
  • Table 200. United States Renal Biomarker, by Application USD Million (2021-2026)
  • Table 201. United States Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 202. Canada Renal Biomarker, by Type USD Million (2021-2026)
  • Table 203. Canada Renal Biomarker, by Application USD Million (2021-2026)
  • Table 204. Canada Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 205. Mexico Renal Biomarker, by Type USD Million (2021-2026)
  • Table 206. Mexico Renal Biomarker, by Application USD Million (2021-2026)
  • Table 207. Mexico Renal Biomarker, by Diagnostic Technique USD Million (2021-2026)
  • Table 208. Renal Biomarker: by Type(USD/Units)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Renal Biomarker: by Type USD Million (2015-2020)
  • Figure 5. Global Renal Biomarker: by Application USD Million (2015-2020)
  • Figure 6. Global Renal Biomarker: by Diagnostic Technique USD Million (2015-2020)
  • Figure 7. South America Renal Biomarker Share (%), by Country
  • Figure 8. Asia Pacific Renal Biomarker Share (%), by Country
  • Figure 9. Europe Renal Biomarker Share (%), by Country
  • Figure 10. MEA Renal Biomarker Share (%), by Country
  • Figure 11. North America Renal Biomarker Share (%), by Country
  • Figure 12. Global Renal Biomarker: by Type USD/Units (2015-2020)
  • Figure 13. Global Renal Biomarker share by Players 2020 (%)
  • Figure 14. Global Renal Biomarker share by Players (Top 3) 2020(%)
  • Figure 15. Global Renal Biomarker share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Beckman Coulter Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Beckman Coulter Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Abbott Molecular Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Abbott Molecular Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Bioporto AS (Denmark) Revenue, Net Income and Gross profit
  • Figure 24. Bioporto AS (Denmark) Revenue: by Geography 2020
  • Figure 25. Astute Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Astute Medical Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Randox Laborotories Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Randox Laborotories Ltd (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Siemens Healthineers (Germany) Revenue: by Geography 2020
  • Figure 31. Cobo Scientific Biomedical Research (Denmark) Revenue, Net Income and Gross profit
  • Figure 32. Cobo Scientific Biomedical Research (Denmark) Revenue: by Geography 2020
  • Figure 33. F. Hoffmann-La Roche Ag (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche Ag (Switzerland) Revenue: by Geography 2020
  • Figure 35. Biomerieux (France) Revenue, Net Income and Gross profit
  • Figure 36. Biomerieux (France) Revenue: by Geography 2020
  • Figure 37. Global Renal Biomarker: by Type USD Million (2021-2026)
  • Figure 38. Global Renal Biomarker: by Application USD Million (2021-2026)
  • Figure 39. Global Renal Biomarker: by Diagnostic Technique USD Million (2021-2026)
  • Figure 40. South America Renal Biomarker Share (%), by Country
  • Figure 41. Asia Pacific Renal Biomarker Share (%), by Country
  • Figure 42. Europe Renal Biomarker Share (%), by Country
  • Figure 43. MEA Renal Biomarker Share (%), by Country
  • Figure 44. North America Renal Biomarker Share (%), by Country
  • Figure 45. Global Renal Biomarker: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Beckman Coulter Inc. (United States)
  • Thermo Fisher Scientific Inc. (United States)
  • Abbott Molecular Inc. (United States)
  • Bioporto AS (Denmark)
  • Astute Medical Inc. (United States)
  • Randox Laborotories Ltd (United Kingdom)
  • Siemens Healthineers (Germany)
  • Cobo Scientific Biomedical Research (Denmark)
  • F. Hoffmann-La Roche Ag (Switzerland)
  • Biomerieux (France)
Additional players considered in the study are as follows:
R&D Systems (United States) , Myriad RBM Inc. (United States)
Select User Access Type

Key Highlights of Report


Dec 2021 234 Pages 90 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Renal Biomarker Quantitative research analysis
Global Renal Biomarker Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Renal Biomarker Market are Beckman Coulter Inc. (United States), Thermo Fisher Scientific Inc. (United States), Abbott Molecular Inc. (United States), Bioporto AS (Denmark), Astute Medical Inc. (United States), Randox Laborotories Ltd (United Kingdom), Siemens Healthineers (Germany), Cobo Scientific Biomedical Research (Denmark), F. Hoffmann-La Roche Ag (Switzerland) and Biomerieux (France) etc.
A biomarker is also known as a biologic marker is a measurable indicator of a specific biological state, particularly one relevant to the risk for, the presence of, or the stage of the disease. Though historically the term often mentioned to a physical trait or physiological metric, it now normally refers to products of genomic, metobolomic, and proteomic research. Biomarkers can be used clinically to screen for, diagnose, or monitor the movement of diseases and to guide molecularly targeted therapy or assess therapeutic response.

Know More About Global Renal Biomarker Report?

Have a Query? Click Here

Other Related Reports

Online Weight Loss Programs Comprehensive Study by Type (Diet Weight Loss Programs, Exercise Weight Loss Programs, Others), Platform (Web, Mobile Apps), Subscription (Monthly, Quarterly, Annual), End...
$ 3500
Ambulance Services Comprehensive Study by Type (Emergency Ambulance Services, General Ambulance Services), Application (Pre-hospital Support, Post-hospital Support), Services Sector (Private, Public)...
$ 3750
Weight Loss and Obesity Management Comprehensive Study by Application (Fitness Centers, Slimming Centers, Consulting Services, Online Weight Loss Programs), By Diet (Meals, Beverages, Supplements), B...
$ 3750
Medical Automation Technologies Comprehensive Study by Application (Diagnostics & Monitoring,, Therapeutics,, Lab & Pharmacy Automation,, Medical Logistics & Training), Automated Health Assessment An...
$ 3800
Molecular Diagnostic Comprehensive Study by Type (Instruments, Reagents, Others), Application (Infectious Disease, Blood Screening, Genetic Testing, Oncology Testing), Technology (PCR, In Situ Hybrid...
$ 3650
Sciatica Treatment Comprehensive Study by Type (L4 Nerve Root Sciatica, L5 Nerve Root Sciatica, S1 Nerve Root Sciatica, Others), Drugs (Anesthetics, Pain killers, Muscle relaxants, Antidepressants, S...
$ 3750